Can Less Be More in Uro-Oncology? ARASAFE and DISCUS

The Real-World Feasibility Gap

Although molecularly targeted therapies transformed oncology, cytotoxic chemotherapy remains a backbone for many cancers. However, standard doses and cycle countstested in trials are not tolerated by every real-world patient. Treatment optimization using less intensive regimens could improve feasibility, treatment continuation, quality of life and even equitable access .

Presented at ESMO 2025, ARASAFE (prostate, Phase 3) and DISCUS (urothelial, Phase 2) tested this approach through patient-centered outcomes .

1) ARASAFE Phase 3 (Prostate Cancer, LBA92)

Design: In metastatic hormone-sensitive prostate cancer (mHSPC), upfront triple treatment (docetaxel + darolutamide + ADT) was studied by comparing docetaxel intensity : 50 mg/m² every 2 weeks vs 75 mg/m² every 3 weeks.

Background: ARASENS (NEJM 2022) demonstrated survival gains with triple treatment, but severe docetaxel-related neutropenia was ~33% . PROSTY (Lancet Oncol. 2013), 50 mg/m² every 2 weeks had shown similar efficacy with less hematotoxicity .

Primary Focus: Patient safety and sustainability (patient-centred approach), with real-world applicability.

• Safety: Reduced Grade 3–5 hematotoxicity and high-grade adverse events
• Efficacy: Similar to the standard three-weekly regimen (preserving upfront intensification benefits)
• Clinical Implications: The number eligible for triple treatment could expand; febrile neutropenia management and outpatient treatment logistics could become easier.

2) DISCUS Phase 2 (Urothelial Cancer, LBA109)

Design: For locally advanced/metastatic urothelial cancer, first-line platinum + gemcitabine chemotherapy was reduced to 3 cyclesand compared with 6 cycles , followed by planned avelumab maintenance (JAVELIN Bladder 100 background).

Clinical Implications: With 3 cycles, earlier and more frequent transition to avelumab maintenance becomes possible. For patients unable to complete treatment or at risk from toxicity, this can maintain standards while helping to increase access.

What Does This Mean? 5 Points for Practice

1. Feasibility: Less frequent/less intensive chemotherapy may better fit clinical reality .
2. Safety: ARASAFE showed reducedhigh-grade hematotoxicity; DISCUS showed fewer Grade 3–4 AEs.
3. Access: DISCUS, significantly increased transition rates to avelumab maintenance.
4. Efficacy Preserved: Neither study showed meaningful losses in core efficacy measures.
5. Health Economics: Shorter/less intensive protocols may reduce cost, staffing and hospitalization burdens.

Looking Ahead

"Less is more" may improve participation, particularly in older patients, those with comorbidities or limited performance status , and support treatment continuity . Future steps should include biomarker-guided de-escalation, PRO (patient-reported outcome) integration and cost-effectiveness modeling.

Brief Practical Notes

• Prostate Cancer (mHSPC): For triple-treatment candidates with high neutropenia risk, docetaxel 50 mg/m² every 2 weeks may be considered.
• Urothelial Cancer (mUC): If earlier and more frequent transition to avelumab maintenance is the goal, 3 cycles of platinum + gemcitabine may be considered.
• Patient Preference: PRO measures are critical for objectively documenting quality-of-life benefits.

Sources

• Grimm MO, et al. ARASAFE: In mHSPC, with darolutamide + ADT, docetaxel 75 mg/m² every 3 weeks vs 50 mg/m² every 2 weeks (Phase 3). ESMO 2025 – LBA92.
• Grande E, et al. DISCUS: In advanced urothelial cancer, 3 vs 6 cycles before avelumab maintenance of platinum + gemcitabine (Phase 2). ESMO 2025 – LBA109.